---
schema_version: "secwatch.filing_event.v1"
accession: "0001490978-24-000088"
form_type: "8-K"
ticker: "SDGR"
cik: "0001490978"
company_name: "Schrodinger, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:46:51.791149+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Schrödinger Q3 total revenue $35.3M (-17% YoY); announces $150M upfront Novartis collaboration

## Summary
- Software revenue $31.9M (+10% YoY); drug discovery revenue $3.4M (-75% YoY).
- Net loss $38.1M vs $62.0M a year ago; non-GAAP net loss $63.7M.
- Novartis pays $150M upfront; potential milestones up to $2.3B plus royalties.
- 2024 guidance: software rev growth 8-13%; drug discovery rev $20-30M; software gross margin slightly below 2023.
- Cash & equivalents $398.4M at Sept 30, 2024; received $48M from Lilly buyout of Morphic.

## SEC filing metadata
- accession: 0001490978-24-000088
- form_type: 8-K
- ticker: SDGR
- cik: 0001490978
- company_name: Schrodinger, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1490978/000149097824000088/0001490978-24-000088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1490978/000149097824000088/sdgr-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001490978-24-000088
- JSON: https://secwatch.observer/filing/0001490978-24-000088.json
- Plain text: https://secwatch.observer/filing/0001490978-24-000088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.